basi
previou
studi
antivir
agent
sever
acut
respiratori
syndrom
sar
coronaviru
seri
nucleosid
analogu
whose
hydroxyl
group
mask
variou
protect
group
carboxyl
sulfon
ether
synthes
evalu
develop
novel
antihepat
c
viru
hcv
agent
among
sever
omask
analogu
deoxyribosid
eg
obenzoyl
opmethoxybenzoyl
obenzyl
analogu
found
exhibit
effect
antihcv
activ
particular
obenzoyl
analogu
exhibit
highest
potenc
ec
lm
cellbas
hcv
replicon
assay
sinc
ounmask
analogu
ie
deoxyribosid
suffici
potent
ec
lm
mask
hydroxyl
group
seem
effect
method
develop
antihcv
agent
present
hypothes
two
role
omask
analogu
one
role
antihcv
agent
prodrug
odemask
deprotect
deriv
hepat
c
viru
hcv
member
famili
flavivirida
envelop
positivesens
singlestrand
rna
viru
viru
major
caus
agent
nona
nonb
hepat
infect
estim
million
peopl
worldwid
case
acut
phase
infect
hcv
asymptomat
howev
viru
frequent
establish
chronic
hepat
infect
individu
persist
decad
substanti
high
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
current
vaccin
avail
hcv
approv
drug
combin
interferona
ifna
ribavirin
although
use
pegyl
ifna
instead
unmodifi
one
result
improv
therapeut
effect
sustain
virolog
respons
still
poor
moreov
case
signific
side
effect
caus
therefor
efficaci
therapi
urgent
requir
ensur
public
health
date
number
nucleosid
analogu
includ
ribavirin
synthes
test
antihcv
activ
among
modifi
ribonucleosid
analogu
cmethyl
analogu
fluoro
analogu
omethyl
analogu
exhibit
potent
antihcv
activ
cellbas
hcv
replicon
assay
fig
particularli
valopicitabin
prodrug
current
phase
ii
clinic
trial
recent
antihcv
properti
substitut
ribonucleosid
also
report
roch
group
concern
antivir
mechan
common
nucleosid
analogu
known
analogu
convert
correspond
cellular
andor
viral
enzym
compet
natur
triphosph
substrat
incorpor
viral
nucleic
acid
viral
replic
therefor
hydroxyl
group
indispens
antihcv
activ
nucleosid
analogu
recent
report
carbocycl
oxetanocin
analogu
one
whose
hydroxyl
group
correspond
hydroxyl
group
ribonucleosid
mask
benzoyl
group
show
antivir
activ
sever
acut
respiratori
syndrom
sar
coronaviru
fig
interestingli
antivir
activ
ec
lm
much
efficaci
unmask
almost
activ
ec
lm
seem
indic
inconsist
necess
hydroxyl
group
compound
result
attract
interest
led
us
expect
uniqu
trend
could
contribut
develop
antihcv
agent
well
thu
sever
nucleosid
analogu
includ
design
candid
compound
agent
fig
paper
report
synthes
nucleosid
analogu
biolog
evalu
antihcv
agent
compound
prepar
base
previou
report
synthes
compound
carri
treatment
diol
correspond
acyl
sulfonyl
chlorid
ie
benzoyl
chlorid
pivaloyl
chlorid
butyryl
chlorid
pmethoxybenzoyl
chlorid
chlorid
benzenesulfonyl
chlorid
respect
shown
scheme
case
compound
convent
condit
trimethylbenzoyl
chlorid
dmap
pyridin
requir
long
reaction
time
led
gradual
decomposit
probabl
moieti
react
amin
base
degre
due
electrophil
natur
side
reaction
slightli
suppress
use
lownucleophil
base
n
ndiisopropylethylamin
instead
pyridin
dmap
compound
also
prepar
via
altern
rout
illustr
scheme
regioselect
protect
hydroxyl
group
deoxyadenosin
yield
benzoat
yield
subsequ
convert
silyl
ether
yield
transform
deriv
yield
tb
group
cleav
afford
yield
compound
also
use
intermedi
synthesi
shown
scheme
exposur
sodium
methylthiol
result
format
debenzoyl
analogu
yield
reacyl
yield
unfortun
use
thiourea
place
sodium
methylthiol
led
decomposit
result
product
final
remov
tb
group
afford
yield
synthesi
illustr
scheme
diacet
prepar
describ
previou
report
treat
dimethylamin
furnish
yield
subsequ
regioselect
benzoyl
hydroxyl
group
afford
yield
meanwhil
synthes
turn
unexpectedli
difficult
instabl
molecul
strongli
basic
acid
condit
exampl
exposur
bnbrnah
bnoc
nh
ccl
cf
h
afford
complex
mixtur
thu
stepwis
protectiondeprotect
process
requir
illustr
scheme
synthesi
synthesi
monoacet
prepar
employ
partli
modifi
santaniello
procedur
convert
silyl
ether
yield
use
mix
solvent
pyridinedmf
effect
reduc
competit
silyl
group
protect
amino
group
pivaloyl
chlorid
follow
remov
acetyl
group
afford
yield
two
step
addit
dmap
meoh
npivaloyl
step
effect
convert
n
ndipivaloyl
byproduct
desir
chemoselect
benzyl
hydroxyl
group
success
carri
use
equiv
potassium
tertbutoxid
equiv
benzyl
bromid
thf
provid
yield
remov
pivaloyl
group
yield
result
amino
group
substitut
chloro
group
provid
subsequ
deprotect
afford
yield
two
step
compound
synthes
employ
almost
method
describ
scheme
overal
yield
synthes
nucleosid
analogu
assay
abil
inhibit
hcv
rna
replic
subgenom
replicon
cell
line
lucneo
result
shown
tabl
cell
contain
hcv
subgenom
replicon
rna
encod
luciferas
report
gene
marker
potenc
analogu
hcv
replicon
express
ec
quantifi
luciferas
assay
twoday
incub
period
correspond
compound
addit
associ
cytotox
express
cc
tabl
evalu
tetrazolium
xtt
base
assay
accord
manufactur
protocol
expect
benzoyl
carbocycl
oxetanocin
analogu
exhibit
stronger
antihcv
activ
shown
unprotect
ec
lm
lm
respect
trend
seem
consist
antisarscoronaviru
activ
mention
fig
ec
lm
lm
respect
howev
compound
display
cytotox
effect
level
close
ec
valu
cc
lm
antivir
index
therefor
evalu
compound
undertaken
structureact
relationship
sar
sugar
moieti
evalu
effect
sugar
moieti
sever
deriv
possess
ribofuranosyl
structur
deoxyribofuranosyl
structur
deoxi
deoxi
acycl
backbon
test
among
deoxyribonucleosid
deriv
exhibit
highest
potenc
hcv
replicon
ec
lm
ninefold
potent
ribavirin
cc
lm
addit
obenzoyl
analogu
potent
correspond
unprotect
analogu
ec
lm
obz
vs
lm
oh
trend
also
observ
acycl
analogu
ec
lm
vs
lm
contrast
case
ribofuranosyl
structur
hydroxyl
analogu
slightli
potent
compar
obenzoyl
analogu
ec
lm
respect
result
indic
import
mask
hydroxyl
group
deoxyribofuranosyl
structur
also
interest
note
deoxyribonucleosid
deriv
potent
correspond
ribonucleosid
deriv
spite
fact
hcv
rna
viru
antihcv
agent
bear
ribofuranosyl
structur
bioisoster
sar
omoieti
next
step
evalu
inhibitori
activ
compound
whose
hydroxyl
group
mask
variou
protect
group
ie
pivaloyl
butyryl
trimethylbenzoyl
benzenesulfonyl
benzyl
allyl
group
examin
effect
substitu
group
posit
among
compound
ec
valu
close
structur
analogu
pmethoxybenzoyl
analogu
compar
ec
lm
respect
howev
led
undesir
increas
cytotox
cc
lm
notabl
type
protect
group
ether
group
compound
sulfon
group
compound
also
exhibit
good
antihcv
activ
ec
lm
respect
overal
appear
protect
group
contain
phenyl
ring
prefer
antivir
activ
sar
posit
purin
base
effect
substitu
purin
investig
evalu
compound
among
analogu
deriv
exhibit
good
potenc
ec
lm
low
cytotox
cc
lm
deriv
show
weak
potenc
ec
lm
unfortun
other
ie
hypoxanthin
analogu
analogu
show
signific
potenc
ec
lm
accordingli
chloro
group
purin
consid
import
antihcv
activ
luciferas
assay
describ
reveal
compound
exhibit
maximum
potenc
among
analogu
next
order
confirm
antihcv
activ
replicon
rna
level
quantifi
perform
realtim
rtpcr
analysi
fig
show
result
obtain
ribavirin
posit
control
compound
reduc
replicon
rna
amount
approxim
lm
lm
almost
consist
result
luciferas
assay
ec
lm
among
molecul
two
compound
hypothes
speci
real
antivir
activ
one
omask
deoxyadenosin
analogu
deprotect
activ
form
triphosph
sinc
carboxyl
ester
bond
often
hydrolyz
cultur
cell
report
earlier
howev
chemic
stabl
omask
analogu
bn
allyl
ether
respect
show
antihcv
potenc
extent
moreov
deoxyadenosin
deriv
would
transform
inact
deoxyadenosin
hydrolysi
also
show
potenc
thu
take
result
consider
would
reason
consid
omask
analogu
possess
antihcv
potenc
hand
would
also
reason
consid
compound
triphosph
one
real
activ
speci
sinc
also
exhibit
antihcv
activ
though
moder
word
compound
oper
prodrug
therefor
stage
believ
compound
eg
would
function
speci
antivir
activ
cell
seri
nucleosid
analogu
synthes
abil
inhibit
hcv
rna
replic
evalu
among
sever
omask
analogu
deoxyribosid
exhibit
effect
antihcv
activ
particular
obenzoyl
analogu
exhibit
highest
activ
present
hypothes
two
role
omask
analogu
one
role
antihcv
agent
prodrug
odemask
deprotect
deriv
two
notabl
structur
featur
potent
compound
one
mask
hydroxyl
group
deoxyribofuranosyl
structur
relat
substitu
group
posit
purin
base
chloro
group
seem
prefer
uniqu
featur
rare
seen
common
antihcv
agent
therefor
although
issu
improv
antivir
potenc
remain
resolv
hope
present
studi
contribut
develop
new
class
hcv
therapeut
agent
stir
solut
mg
mmol
dmap
mg
mol
pyridin
ml
ad
pivaloyl
chlorid
mmol
icewat
temperatur
mixtur
stir
temperatur
min
room
temperatur
min
workup
process
perform
manner
describ
bd
purin
stir
solut
mg
mmol
n
ndiisopropylethylamin
mmol
acetonitril
ml
ad
chlorid
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
workup
process
perform
manner
describ
crude
materi
purifi
prepar
thin
layer
chomatographi
merck
ethyl
acetatehexan
give
mg
white
semisolid
stir
solut
mg
mmol
pyridin
ml
ad
benzenesulfonyl
chlorid
time
interv
min
mmol
room
temperatur
mixtur
stir
temperatur
h
total
workup
process
perform
manner
describ
crude
materi
purifi
silica
gel
column
chromatographi
methanolchloroform
give
mg
white
semisolid
stir
solut
mg
mmol
ch
cl
ml
ad
pyridin
ml
benzoyl
chlorid
mmol
icewat
temperatur
mixtur
stir
temperatur
h
subsequ
addit
satur
nahco
solut
mixtur
extract
ethyl
acet
combin
organ
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
solid
mp
stir
solut
mg
mmol
pyridin
ml
ad
imidazol
g
mmol
tertbutyldimethylsilyl
chlorid
g
mmol
room
temperatur
mixtur
stir
overnight
temperatur
subsequ
addit
water
mixtur
stir
min
concentr
reduc
pressur
residu
dissolv
ethyl
acet
ethyl
acet
solut
wash
water
aqueou
hcl
satur
nahco
solut
brine
dri
na
concentr
reduc
pressur
ad
solut
tetraethylammonium
chlorid
mg
mmol
ch
cl
ml
tertbutyl
nitrit
mmol
icewat
temperatur
mixtur
stir
h
temperatur
warm
room
temperatur
h
stir
h
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
pale
yellow
oil
mmol
icewat
temperatur
mixtur
stir
temperatur
h
room
temperatur
h
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
solid
tertbutyldimethylsilyl
stir
solut
mg
mmol
dmf
ml
ad
solut
methyl
mercaptan
sodium
salt
water
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
dilut
mixtur
ethyl
acet
organ
layer
wash
water
satur
nahco
solut
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
stir
solut
mg
mmol
dioxan
ml
ad
dimethylaminewat
solut
ml
room
temperatur
mixtur
stir
overnight
temperatur
solvent
remov
reduc
pressur
result
residu
wash
ether
sever
time
purifi
silica
gel
column
chromatographi
methanolchloroform
give
mg
white
solid
h
c
nmr
spectra
mass
spectrum
ident
report
valu
obenzoyln
n
deoxyadenosin
stir
solut
mg
mmol
pyridin
ml
ad
benzoyl
chlorid
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
subsequ
addit
satur
nahco
solut
mixtur
extract
ethyl
acet
combin
organ
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
semisolid
molecular
siev
mg
lipas
acryl
resin
candida
antarctica
mg
purchas
sigma
suspend
thf
ml
mixtur
stir
h
enzym
filter
wash
meoh
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
methanolchloroform
give
mg
white
solid
h
nmr
spectrum
ident
report
valu
tertbutyldimethylsilyl
deoxyadenosin
stir
solut
mg
mmol
pyridinedmf
ml
ad
tertbutyldimethylsilyl
chlorid
mg
mmol
dmap
mg
mmol
room
temperatur
mixtur
stir
overnight
temperatur
subsequ
addit
water
mixtur
stir
min
extract
ethyl
acet
combin
organ
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acet
give
mg
white
solid
mp
stir
solut
mg
mmol
triethylamin
mmol
ch
cl
ml
ad
pivaloyl
chlorid
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
subsequ
addit
dmap
mg
mol
methanol
ml
mixtur
stir
overnight
room
temperatur
dilut
mixtur
ethyl
acet
organ
layer
wash
water
khso
solut
satur
nahco
solut
brine
dri
na
concentr
reduc
pressur
leav
crude
compound
mg
employ
next
reaction
without
purif
stir
solut
mg
methanol
ml
ad
potassium
carbon
mg
mmol
icewat
temperatur
mixtur
stir
temperatur
h
subsequ
addit
acet
acid
water
ml
organ
solvent
remov
reduc
pressur
result
mixtur
extract
ethyl
acet
organ
layer
wash
satur
nahco
solut
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
solid
stir
solut
mg
mmol
thf
ml
ad
potassium
tertbutoxid
mg
mmol
icewat
temperatur
mixtur
stir
temperatur
min
subsequ
addit
benzyl
bromid
mmol
icewat
temperatur
mixtur
stir
temperatur
h
dilut
mixtur
water
aqueou
layer
extract
ethyl
acet
organ
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
colorless
oil
stir
solut
mg
mmol
methanol
ml
ad
potassium
carbon
mg
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
dilut
ch
cl
mixtur
filtrat
subsequ
condens
filtrat
vacuum
result
residu
dilut
ethyl
acet
ethyl
acet
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
solid
mp
stir
solut
mg
mmol
ccl
ml
ad
solut
tetraethylammonium
chlorid
mg
mmol
ch
cl
ml
tertbutyl
nitrit
mmol
icewat
temperatur
mixtur
stir
h
temperatur
warm
room
temperatur
h
stir
h
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
insepar
byproduct
employ
next
reaction
without
purif
stir
solut
mg
thf
ml
ad
thf
solut
tbafacoh
mmol
icewat
temperatur
mixtur
stir
temperatur
h
room
temperatur
h
solvent
remov
reduc
pressur
result
residu
purifi
prepar
thin
layer
chromatographi
merck
methanolchloroform
give
mg
colorless
oil
stir
solut
mg
mmol
thf
ml
ad
potassium
tertbutoxid
mg
mmol
icewat
temperatur
mixtur
stir
temperatur
min
subsequ
addit
allyl
bromid
mmol
icewat
temperatur
mixtur
stir
temperatur
h
dilut
mixtur
satur
nahco
solut
aqueou
layer
extract
ethyl
acet
organ
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
insepar
byproduct
employ
next
reaction
without
purif
stir
solut
mg
methanol
ml
ad
potassium
carbon
mg
mmol
icewat
temperatur
mixtur
stir
room
temperatur
h
dilut
ch
cl
mixtur
filtrat
subsequ
condens
filtrat
vacuum
result
residu
dilut
ethyl
acet
ethyl
acet
layer
wash
water
brine
dri
na
concentr
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
white
solid
ml
ad
solut
tetraethylammonium
chlorid
mg
mmol
ch
cl
ml
tertbutyl
nitrit
mmol
icewat
temperatur
mixtur
stir
h
temperatur
warm
room
temperatur
h
stir
h
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
ethyl
acetatehexan
give
mg
insepar
byproduct
employ
next
reaction
without
purif
stir
solut
mg
thf
ml
ad
thf
solut
tbafacoh
mmol
icewat
temperatur
mixtur
stir
temperatur
h
room
temperatur
h
solvent
remov
reduc
pressur
result
residu
purifi
silica
gel
column
chromatographi
methanolchloroform
give
mg
colorless
oil
compound
h
nmr
aceton
cell
cultur
luciferas
assay
realtim
rtpcr
analysi
perform
describ
previous
cytotox
evalu
tetrazolium
xtt
base
assay
accord
manufactur
protocol
cell
prolifer
kit
ii
xtt
roch
diagnost
cat
